Streetbeat News

JAQC

Jupiter Acquisition Corp

Open

10.34

Mkt cap

62M

Volume

578

High

10.34

P/E Ratio

-23.50

52-wk high

11.07

Low

10.34

Div yield

N/A

52-wk low

6.95

Jupiter Acquisition has mutually agreed to terminate its merger with Filament Health Corp. The special stockholders meeting set for December 28, 2023, is canceled. Jupiter will redeem all outstanding Class A common stock from its IPO effective December 26, 2023, as it cannot complete a business combination within the timeframe specified in its Charter.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 7:29 am

Filament Health (OTCQB:FLHLF) has released its Q1 2023 financial results, showing a decrease in total cash and an accumulated deficit of $19.6 million. The company has expressed uncertainties about its ability to execute its business plan and continue operations without additional financing. Filament has announced its intention to list on the NASDAQ through a business combination with Jupiter Acquisition Corp. (NASDAQ:JAQC). The company has also reported progress in its drug development program, including FDA approval of two clinical studies and a global licensing agreement with NeoLumina Bioscience Inc.

Portfolio Pulse from Lara Goldstein

August 15, 2023 | 10:21 pm

Filament Health (OTCQB:FLHLF) has entered into a definitive agreement with Jupiter Acquisition Corp. (NASDAQ:JAQC) for a $210M SPAC deal. The new business combination ascribes Filament $176 million in pre-money equity and will give holders of outstanding shares $0.85 per share of the new company. The deal is expected to close in Q4 2023. Filament's lead drug candidate PEX010 is currently undergoing 15 clinical trials for the potential treatment of various disorders.

Portfolio Pulse from Lara Goldstein

July 19, 2023 | 9:41 pm

Shares of Jupiter Acquisition Corporation have been halted due to pending news. The nature of the news is not yet disclosed.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2023 | 11:56 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.